

Curriculum Vitae

Prof. Dr. med. Ulrich Güller, MHS, FEBS

Wichtigste berufliche Etappen in der Übersicht:

Seit 1/2020	Chefarzt Onkologie- und Hämatologiezentrum Thun-Spiez-Berner Oberland, Spital STS AG, Thun
1/2020 – 09/2025	Mitglied Geschäftsleitung Spital STS AG, Thun
5/2017 – 12/2019	Stv. Chefarzt, Med. Onkologie & Hämatologie, Kantonsspital St. Gallen
11/2015 – 4/2017	Leitender Arzt, Med. Onkologie & Hämatologie, Kantonsspital St. Gallen
1/2014 – 12/2019	Leiter Gastrointestinale Medizinische Onkologie, Kantonsspital St. Gallen
10/2013 – 10/2015	Oberarzt Medizinische Onkologie, Kantonsspital St. Gallen
2013 - 2016	Management im Gesundheitswesen (CAS), Hochschule St. Gallen (HSG)
5/2012	Titularprofessur, Universität Bern
5/2010	Assoziierte Professur, Universität Bern
2009 - 2011	Leitender Arzt und Leiter der Kolorektalen Chirurgie, Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Universität Bern
2008- 2009	2. Klinisches Fellowship Minimal Invasive Chirurgie, Universität Toronto, Toronto/Canada
2006 – 2008	1. Klinisches Fellowship Chirurgische Onkologie (Society of Surgical Oncology [SSO] certified), Universität Toronto, Toronto/Canada
2001 – 2003	Research Fellowship Duke University, Durham, NC/USA: <ul style="list-style-type: none"> - Masterstudiengang: Master of Health Sciences (MHS) - Postdoktorat: American College of Surgeons Oncology Group (ACOSOG) und Center for Excellence in Surgical Outcomes (CESO)
01/1999– 12/2005	Allgemeinchirurgische Ausbildung, Departement Chirurgie, Universität Basel (inkl. 12 Monate Rotation St. Claraspital Basel) und Ospedale Civico Lugano

Dissertation

1998

„Lymphozytäre Colitis“ (Leitung: Prof. Michael Fried, Universitäts-
spital Zürich), publiziert in Gut 1998; 43: 629.

Akademische Auszeichnungen

- 128 peer-reviewte Publikationen
- Anzahl Referenzierungen: 8`901 (researchgate.net)
- Meist referenzierte Publikation: 594x (researchgate.net)
- Hirsch-Faktor (h-index): 54 (researchgate.net)
- Research Interest Score: >98% Perzentile (researchgate.net)
- > 1.3 Million SFR Funding als Principal Investigator

- 2024 **Best Clinical Abstract Award Swiss Oncology & Hematology Congress 2024.** Adjuvant Aspirin treatment in PIK3CA mutated colon cancer patients – the phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial. **Güller U**, Joerger M.
- 2017 **Jahrespreis der Schweizerischen Gesellschaft für Chirurgie:** Comparative analysis of tumor cell dissemination to the sentinel lymph nodes and to the bone marrow in patients with non-metastasized colon cancer. A prospective multicenter study. Weixler B, Viehl CT, Warschkow R, **Güller U**, Ramser M, Sauter G, Zuber M. **JAMA Surgery** 2017; 152: 912.
- 2014 **Grant for Oncology Innovation (GOI).** Prospective double-blinded, placebo-controlled, randomized trial of adjuvant aspirin treatment in PIK3CA mutated colon cancer patients, PI: **Ulrich Güller** (weltweite Ausschreibung: prämiert aus 143 eingegangenen Projekten aus 25 Ländern).
- 2014 **Colorectal Cancer Research Scholar Award** of the Society of Surgical Oncology (SSO) und der Colorectal Cancer Challenge (CCC) Foundation
Weixler B, Warschkow R, **Güller U**, Zettl A, von Holzen U, Schmied B, Zuber M. Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival. **BMC Cancer** 2016; 16: 106.
- 2014 **Zollikofer Preis**, Schweizerische Arbeitsgemeinschaft für Laparoskopische und Thorakoskopische Chirurgie. Concomitant cholecystectomy during laparoscopic Roux-en-Y gastric bypass in obese patients is not justified: a meta-analysis. Warschkow R, Tarantino I, Ukejinii K, Beutner U, **Güller U**, Schmied B, Müller S, Schulthess B, Thurnherr M. **Obesity Surgery** 2013; 23(3): 397.
- 2013 **Zollikofer Preis**, Schweizerische Arbeitsgemeinschaft für Laparoskopische und Thorakoskopische Chirurgie. High risks for adverse outcomes after gastric bypass surgery following failed gastric banding: a population-based analysis. Worni M, Ostbye T, Pietrobon R, **Güller U**. **Annals of Surgery** 2013; 257: 279.
- 2012 **Chirurgiepreis** der Schweizerischen Gesellschaft für Viszeralchirurgie und Gastroenterologie. Tarantino I, Warschkow R, Worni M, Merati-Kashani K, Köberle D, Schmied BM, Müller SA, Steffen T, Cerny T, **Güller U**. Elevated preoperative CEA is associated with worse survival instage I-III rectal cancer patients. **British Journal of Cancer** 2012 Jul 10;107(2):266.
- 2011 **Zollikofer Preis**, Schweizerische Arbeitsgemeinschaft für Laparoskopische und Thorakoskopische Chirurgie (SALTC). Brugger L, Rosella L, Candinas D, **Güller U**. Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7446 patients. **Annals of Surgery** 2011; 253(2):309-13.
- 2010 **Karl Storz Award der European Association of Endoscopic Surgery (EAES).** Population-based analysis of 4126 patients with acute cholecystitis: defining the optimal time point for laparoscopic cholecystectomy. Banz V, Gsponer T, Candinas D, **Güller U**. **Annals of Surgery** 2011; 254: 964.

- 2009 **Pfizer Oncology Research Award**. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. **Güller U**, Langer I (Co-Recipients) **Breast Cancer Research and Treatment** 2009;113(1):129.
- 2008 **Felix Largiadèr Award**. Sentinel lymph node procedure in resectable colon cancer – results from the prospective Swiss multicenter study. Viehl CT, **Güller U**, et al.
- 2008 **Selection for the British Journal Annual Review Issue 2008**. Caveats in the interpretation of the surgical literature. **Güller U**. **British Journal of Surgery** Annual Review Issue 2008, 95: 541.
- 2007 **Best Poster Award**, Annual Meeting of the Society of Surgical Oncology (SSO) 2007, Washington DC/USA. Trends in adjuvant treatment of gastric cancer: an analysis of 9,528 patients. **Güller U** et al.
- 2007 **Zollikofer Preis**, Schweizerische Arbeitsgemeinschaft für Laparoskopische und Thorakoskopische Chirurgie. Early introduction of laparoscopic sigmoidectomy during residency: a safe and feasible training concept. Daetwiler S, **Güller U**, Schoeb O, Adamina M. **British Journal of Surgery** 2007; 94: 634.
- 2006 **Selection for the British Journal Annual Review Issue 2006**. Propensity scores: A comprehensive review for surgeons. Adamina M, **Güller U**, et al. **British Journal of Surgery** Annual Review Issue 2006, 93: Suppl. 4.
- 2005 **Jahrespreis der Schweizerischen Gesellschaft für Chirurgie** 2005: Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micro-metastases: prospective analysis of 150 patients after SLN biopsy. Langer I, Marti W, **Güller U**, et al. **Annals of Surgery** 2005; 241:152.
- 2004 **British Journal of Surgery Award**: Peri-operative detected disseminated tumour cells represent an independent prognostic factor in colorectal cancer patients. Bosch B, **Güller U**, et al. **British Journal of Surgery** 2003, 90(7): 882.
- 2004 **Wahl in das Yearbook of Surgery**: Laparoscopic versus open appendectomy: outcomes comparison based on a large administrative database. **Güller U** et al. **Annals of Surgery** 2004; 239:43.
- 2004 **Jahrespreis der Schweizerischen Gesellschaft für Thorax-, Herz- und Gefässchirurgie** : Outcomes of early extubation following bypass surgery in the elderly. **Güller U** et al. **Annals of Thoracic Surgery** 2004; 77: 781.
- 2003 **Bester Student des Jahres 2003**, Masterstudiengang, Duke Universität, Durham/USA.
- 2002 **Forschungspreis der Schweizerischen Gesellschaft für Chirurgie**: Disseminated single tumor cells as detected by real-time quantitative PCR represent a prognostic factor in patients undergoing surgery for colorectal cancer, Güller et al., **Annals of Surgery** 2002, 236(6):785.

Erwerb von Drittmitteln

- 2025 Projekt **Cancer Survivorship Sprechstunde**, Onkologie- & Hämatologiezentrum Spital STS AG (Co-Investigator, Krebsstiftung Thun-Berner Oberland, 100'000SFR)
- 2023 Projekt **Geriatrisch-Onkologische Sprechstunde**, Onkologie- & Hämatologiezentrum Spital STS AG (Co-Investigator, Krebsstiftung Thun-Berner Oberland, 36'000SFR)
- 2016 **Prospective double-blinded, placebo-controlled, randomized trial of adjuvant aspirin treatment in PIK3CA mutated colon cancer patients**, (Principal Investigator, Promedica Stiftung, 200'000SFR)
- 2016 **Cancer treatment in the elderly** (Co-Investigator, Swiss Cancer Foundation, 46'000SFR).
- 2015 **Prospective double-blinded, placebo-controlled, randomized trial of adjuvant aspirin treatment in PIK3CA mutated colon cancer patients**, (Principal Investigator, Swiss Cancer League, 351'650SFR)
- 2015 **Liver metastases in colorectal carcinoma: Accuracy of Contrast-enhanced ultrasound (CEUS) in comparison with computer tomography on new diagnosed CRC with impact on therapy strategy? A prospective swiss single center study.** (Co-Investigator, Clinical Trial Unit St. Gallen, 15'560SFR)
- 2014 **Prospective double-blinded, placebo-controlled, randomized trial of adjuvant aspirin treatment in PIK3CA mutated colon cancer patients**, (Principal Investigator, Swiss National Foundation, 454'000SFR)
- 2014 Grant for Oncology Innovation (GOI). **Prospective double-blinded, placebo-controlled, randomized trial of adjuvant aspirin treatment in PIK3CA mutated colon cancer patients**, (Principal Investigator, Grant for Oncology Innovation, 300'000 Euro)
- 2014 **High-risk cancer surgery in Switzerland: Relationship between hospital volume and patient outcomes** (Principal Investigator, Swiss Cancer Foundation, 54'720SFR)
- 2009 **Trend analysis of laparoscopic procedures from 1995 through 2006: quality control based on a large Swiss prospective database.** (Principal Investigator, Johnson and Johnson, 20'000SFR)
- 2006 **Active specific immunotherapy for melanoma patients (stages IIb to IV) with a recombinant vaccinia virus encoding 5 melanoma associated epitopes and 3 co-stimulatory molecules, and influenza virosomes. A multi-center phase I/II open labeled clinical trial.** (Co-Investigator, Freiwillige Akademische Gesellschaft Basel, Basel/Switzerland, 100'000SFR)
- 2006 **Active specific immunotherapy for melanoma patients (stages IIb to IV) with a recombinant vaccinia virus encoding 5 melanoma associated epitopes and 3 co-stimulatory molecules, and influenza virosomes. A multi-center phase I/II open labeled clinical trial.** (Co-Investigator, Cancer League of Basel, Basel/Switzerland, 115'000SFR)

- 2004 **Swiss Multicenter Study of Sentinel Lymph Node (SLN) Procedure in Colon Cancer.** (Co-Investigator, Swiss Society of Clinical Cancer Research/SAKK, 20'000SFR)
- 2002 American College of Surgeons Oncology Group Z0360: **A trial of lymphatic mapping and sentinel node lymphadenectomy for patients with T1 or T2 clinically N0 oral cavity squamous cell carcinoma.** National Institutes of Health, Bethesda/MD (Protocol Development/ACOSOG; Cooperative Group Grant)
- 2002 American College of Surgeons Oncology Group Z0190: **A prospective study of the prognostic significance of microsatellite instability in patients with early age-of-onset colorectal cancer.** National Institutes of Health, Bethesda/MD (Protocol Development/ACOSOG, Cooperative Group Grant)
- 2001-2003 Schweizer Nationalfonds, Bern/Switzerland, Training Grant für Research Fellowship an der Duke Universität (71'000SFR)
- 2002 Freiwillige Akademische Gesellschaft, Basel/Switzerland, Training Grant für Research Fellowship an der Duke Universität (20'000SFR)
- 2002/2003 Fondazione Gustav e Ruth Jacob, Lugano/Switzerland, Training Grant für Research Fellowship an der Duke Universität (30'000SFR)
- 2001/2002 Krebsliga Basel, Basel/Switzerland, Training Grant für Research Fellowship an der Duke Universität (10'000SFR)

Board Mitgliedschaften

- Seit 2020 Verwaltungsrat Radioonkologie Berneroberrland (ROBO), 2024 Vize-VRP
- Seit 2018 Board Member of the Swiss Academy of Multidisciplinary Oncology (SAMO)
- 2017 - 2019 Research Board Member, United European Gastroenterology (UEG)
- 2017 - 2019 Board Member, European Society of Digestive Oncology (ESDO)
- 2015 - 2019 Board Member Swiss Peritoneal Cancer Group
- 2013 – 2017 Advisory Council, European Society of Digestive Oncology (ESDO)
- Seit 2013 Board Member info@onkologie
- 2009 - 2011 Vorstandsmitglied der Schweizerischen Arbeitsgemeinschaft für Laparoskopische und Thorakoskopische Chirurgie (SALTC)
- 2007 – 2009 Associate Editor, Hepatobiliary Cochrane Group
- 2005 - 2006 Sekretär der Association for Research in Surgery (ARS) der Schweizerischen Gesellschaft für Chirurgie
- 2003 - 2012 Mitglied des Wissenschaftlichen Komitees der Schweizerischen Arbeitsgemeinschaft für Laparoskopische und Thorakoskopische Chirurgie (SALTC)
- 2003 -2013 Vorstandsmitglied der Association for Research in Surgery (ARS) der Schweizerischen Gesellschaft für Chirurgie
- 2003 - 2011 Editorial Board Swiss Knife (Schweizerische Chirurgenzeitschrift)

PUBLIKATIONSLISTE

Peer-reviewte Artikel (Erst- oder Letztautor)

1. **Güller U**, Hayoz S, Horber D, Jochum W, De Dosso S, Koeberle D, Schacher S, Inauen R, Stahl M, Delaunoit T, Ettrich T, Bodoky G, Michel P, Koessler T, Rothgiesser K, Calmonte S, Joerger M. Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial. **Clinical Cancer Research** 2025; 31: 3142.
2. **Güller U**, Warschkow R, Ackermann C, Schmid B, Cerny T, Ess S. Lower hospital volume results in higher mortality after esophageal, gastric, pancreatic and rectal cancer resection: a Swiss population-based analysis. **Swiss Medical Weekly** 2017; 147:w14473.
3. Fehr M, Müller J, Knitel M, Fornaro J, Horber D, Koeberle D, Cerny T, **Güller U**. Early postoperative FDG-PET-CT results in a relevant upstaging in the pN2 - subgroup of stage III colorectal cancer patients. **Clinical Colorectal Cancer** 2017; 16: 343.
4. **Güller U**, Tarantino I, Ulrich A, Cerny T, Schmied B, Warschkow R. Revisiting a dogma: Similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis. **Gastric Cancer** 2017; 20: 49.
5. Warschkow R, Sulz M, Marti L, Tarantino I, Schmied B, Cerny T, **Güller U**. Better survival in right-sided versus left-sided localized colon cancer. A population-based propensity score SEER analysis. **BMC Cancer** 2016; 16: 554.
6. Warschkow R, **Güller U** (co-first author), Tarantino I, Cerny T, Schmied B, Thuerlimann B, Joerger M. Improved survival after primary tumor surgery in metastatic breast cancer: A propensity-adjusted, population-based SEER trend analysis. **Annals of Surgery** 2016; 263: 1188.
7. **Güller U**, Tarantino I, Cerny T, Schmied BM, Warschkow R. Population-based SEER trend analysis of overall and cancer-specific survival in 5138 patients with gastrointestinal stromal tumor. **BMC Cancer** 2015;15(1):557.
8. Tarantino I, Warschkow R, Worni M, Ulrich A, Cerny T, Schmied B, **Güller U**. Prognostic relevance of palliative primary tumor removal in 37,793 metastatic colorectal cancer patients; a population-based, propensity score adjusted trend analysis. **Annals of Surgery** 2015; 262:112.
9. Langer I, **Güller U** (co-first author), Worni M, Berclaz G, Singer G, Schaer G, Fehr M, Hess T, Viel CT, Bronz L, Schnarwyler B, Wight E, Infanger E, Burger D, Koechli O, Zuber M. Bone marrow micrometastases do not impact disease-free and overall survival in early stage, sentinel lymph node negative breast cancer patients. **Annals of Surgical Oncology** 2014; 21: 401.
10. Worni M, **Güller U** (co-first author), White R, Castleberry, Pietrobon R, Cerny T, Köberle D. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the SEER registry from 1988 to 2008. **Pancreas** 2013; 42(7): 1157.
11. Tarantino I, Warschkow R, Worni M, Köberle D, Schmied B, Müller S, Steffen T, Cerny T, **Güller U**. Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. **British Journal of Cancer** 2012; 107: 266.
12. **Güller U**, Zettl A, Worni M, Cabalzar D, Viehl C, Langer I, Demartines N, Zuber M. Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): a new road to better staging? **CANCER** 2012; 118: 6039.
13. Warschkow R, **Güller U** (co-first author), Köberle D, Müller SA, Steffen T. Thurnherr M, Schmied B, Tarantino I. Peri-operative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection. A propensity score analysis. **Annals of Surgery** 214; 259: 131.
14. Gass M, Banz VM, Rosella L, Adamina M, Candinas D, **Güller U**. TAPP or TEP? Population-Based Analysis of Prospective Data on 4,552 Patients Undergoing Endoscopic Inguinal Hernia Repair. **World J Surg** 2012 Dec; 36(12): 2782.
15. Worni M, Ostebye T, Pietrobon R, **Güller U**. Laparoscopic appendectomy outcomes on the weekend and during the week are no different: a national study of 151,774 patients. **World Journal of Surgery** 2012; 36: 1527.

16. Worni M, Ostebye T, Pietrobon R, **Güller U**. High risks for adverse outcomes after gastric bypass surgery following failed gastric banding: a population-based trend analysis of the United States. **Annals of Surgery** 2013; 257: 279.
17. Worni M, Ostebye T, Pietrobon R, **Güller U**. Worse outcomes in patients undergoing urgent surgery for left-sided diverticulitis admitted on weekends vs weekdays: a population-based study of 31 832 patients. **Archives of Surgery** 2012; 147: 649.
18. Gass M, Rosella L, Banz V, Candinas D, **Güller U**. Bilateral total extraperitoneal inguinal hernia repair (TEP) has similar outcomes compared to unilateral TEP: Population-based analysis of prospective data of 6,505 patients. **Surgical Endoscopy** 2012; 26: 1364.
19. Viehl CT, **Güller U** (co-first author), Cecini R, Langer I, Ochsner A, Terracciano L, Riehle HM, Laffer U, Oertli D, Zuber M. Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer - Results of the Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer. **Annals of Surgical Oncology** 2012; 19: 1959.
20. Banz V, Gsponer T, Candinas D, **Güller U**. Defining the best time point for laparoscopic cholecystectomy in patients with acute cholecystitis. Population-based analysis based on 4 113 patients. **Annals of Surgery** 2011; 254: 964.
21. **Güller U**, Rosella L, McCall J, Brugger LE, Candinas D. Negative appendectomy and perforation rates in 7 964 laparoscopic appendectomies. **British Journal of Surgery** 2011; 98: 589.
22. Brugger L, Rosella L, Candinas D, **Güller U**. Improving outcomes after laparoscopic appendectomy: a population-based, 12-year trend analysis of 7 446 patients, **Annals of Surgery** 2011 Feb;253(2):309-13.
23. Businger A, Stefanelli U, Güller U. Prevalence of burnout among surgical residents and surgeons in Switzerland. **Archives of Surgery** 2010; 145: 1013.
24. Zingg U, Rosella L, **Güller U**. Population-based trend analysis of laparoscopic Nissen and Toupet funduplications for gastroesophageal reflux disease. **Surgical Endoscopy** 2010 Dec;24(12):3080-5.
25. **Güller U**, Rosella L, Karanicolas P, Adamina M, Hahnloser D. Laparoscopic sigmoid resection: are we getting better? Population-based trend analysis of 2,813 patients. **British Journal of Surgery** 2010; 97: 79 (Impact factor: 4.092).
26. Lawrentchuk N, McCall J, **Güller U**. Critical appraisal of meta-analyses: an introductory guide for the practicing surgeon. **Patient Safety in Surgery** 2009; 3:16.
27. Adamina M, Tomlinson G, **Güller U**. Bayesian statistics in oncology: a guide for the clinical investigator. **Cancer** 2009; 11:5371.
28. **Güller U**, Klein LV, Hagen J. Safety and effectiveness of bariatric surgery: Roux-en-Y gastric bypass is superior to gastric banding in the management of morbidly obese patients. **Patient Safety in Surgery** 2009; 3: 20.
29. Ridgeway PR, **Güller U**. Interpreting study designs in surgical research – a practical guide for surgeons and surgical residents. **Journal of the American College of Surgeons** 2009; 208: 635.
30. **Güller U**. Caveats in the interpretation of surgical literature. **British Journal of Surgery** (Impact factor: 4.092) 2008; 95: 541.
31. Fueglistaler P, Adamina M, **Güller U**. Non inferiority trials in surgical oncology. **Annals of Surgical Oncology** (Impact Factor: 3.33) 2007; 14: 1532.
32. Weber WP, **Güller U** (co-first author), Jain NB, Pietrobon R, Oertli D. Surgeon and hospital caseload impact the likelihood of performing laparoscopic versus open sigmoid resection for diverticular disease - a study based on 55,949 patients. **Archives of Surgery** (Impact Factor: 3.06) 2007; 245: 452.
33. **Güller U**, Turek J, Eubanks S, DeLong E, Oertli D, Feldman J. Detecting pheochromocytoma: defining the most sensitive test. **Annals of Surgery** (Impact Factor: 5.94) 2006; 243: 102.
34. **Güller U**. Surgical outcomes research based on administrative data: inferior or complementary to prospective randomized clinical trials? **World Journal of Surgery** (Impact Factor: 1.91) 2006; 30: 255.
35. **Güller U**, Safford S, Pietrobon R, Heberer M, Oertli D, Jain N. High hospital volume is associated with better outcomes for breast cancer surgery: analysis of 233, 247 patients. **World Journal of Surgery** (Impact Factor:1.91) 2005; 29: 994.

36. Nielsen KC, **Güller U** (co-first author), Steele SM, Klein SM, Greengrass RA, Pietrobon R. Influence of obesity on surgical regional anesthesia in the ambulatory setting. An analysis of 9,038 blocks. **Anesthesiology** (Impact Factor: 3.50) 2005; 102: 181.
37. **Güller U**, Hervey S, Purves H, Muhlbaier LH, Peterson ED, Eubanks S, Pietrobon R. Laparoscopic versus open appendectomy: outcomes comparison based on a large administrative database. **Annals of Surgery** (Impact Factor: 5.94) 2004;239(1):43.
38. **Güller U**, Anstrom KJ, Holman WL, Allman RM, Sansom M, Peterson ED. Outcomes of early extubation following bypass surgery in the elderly. **Annals of Thoracic Surgery** (Impact Factor: 2.05) 2004; 77: 781.
39. **Güller U**, Jain N, Peterson ED, Muhlbaier LH, Eubanks S, Pietrobon R. Laparoscopic appendectomy in the elderly. **Surgery** (Impact Factor: 2.63) 2004; 135 (5): 479.
40. **Güller U**, Jain N, Curtis LH, Oertli D, Heberer M, Pietrobon R. Insurance status and race represent independent predictors of undergoing laparoscopic surgery for appendicitis: secondary data analysis of 145,546 patients. **Journal of the American College of Surgeons** (Impact Factor: 2.07) 2004; 199: 567.
41. **Güller U**, DeLong ED. Interpreting statistics in medicine - a vade mecum for surgeons. **Journal of the American College of Surgeons** (Impact Factor: 2.37) 2004; 198: 441.
42. Braga L, Semelka RC, Pietrobon R, Martin D, De Barros N, **Güller U**. Does hypervascularity of liver metastases as detected on MRI predict disease progression in breast cancer patients? **American Journal of Roentgenology** (Impact Factor: 2.42) 2004; 182 (5): 1207.
43. **Güller U**, Jain N, Hervey S, Purves H, Pietrobon R. Laparoscopic versus open colectomy for diverticular disease: outcomes comparison based on large nationwide databases. **Archives of Surgery** (Impact Factor: 2.75) 2003, 138: 1179.
44. **Güller U**, Blumenstein B. Trends in clinical trials in surgical oncology – implications for outcomes research. **Clinical Therapeutics** (Impact Factor: 2.67) 2003, 25 (2): 684.
45. **Güller U**, Nitzsche EU, Moch H, Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients? **Journal of the National Cancer Institute** (Impact Factor: 13.84) 2003; 16;95(14):1040.
46. **Güller U**, Zajac P, Schnider A, Bosch B, Vorbürger S, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time quantitative PCR represent a prognostic factor in patients undergoing surgery for colorectal cancer. **Annals of Surgery** (Impact Factor: 6.07) 2002; 236(6):785.
47. **Güller U**, Nitzsche EU, Schirp U, Torhorst J, Moch H, Langer I, Marti WR, Oertli D, Harder F, Zuber M. Selective axillary surgery in breast cancer patients based on positron emission tomography with ¹⁸F-fluoro-2-deoxy-D-glucose: not yet! **Breast Cancer Research and Treatment** (Impact Factor: 3.13) 2002; 71:171.
48. **Güller U**, Schonholzer C, Martinoli S. Recurrent hyperparathyroidism in a patient with chronic renal failure after total parathyroidectomy and autotransplantation – case report and review of literature. **Swiss Surgery** 2000; 6: 179.
49. **Güller U**, Zuber M, Harder F. Cecal volvulus – a frequently missed diagnosis. **Swiss Surgery** 2001; 7(4):158.
50. **Güller U**, Oertli D, Terracciano L, Harder F. Neurogenic appendicitis: a frequent, almost unknown condition. **Der Chirurg** (Impact Factor: 0.73) 2001; 72(6): 684.

Peer-reviewte Artikel (Co-Autor)

51. Sawatzki M, **Güller U**, Güsewell S, Husarik D, Semela D, Brand S. A prospective evaluation of the ability of CEUS to improve the detection of colorectal liver metastases by CT, thereby modifying the therapeutic. **Journal of Hepatology** 2021; 74: 419.
52. Weixler B, da Cunha ST, Warschkow R, Demartines N, **Güller U**, Zettl A, Vahrmeijer A, van de Velde C, Viehl CT, Zuber M. Molecular Lymph Node Staging with One-Step Nucleic Acid Amplification and its Prognostic Value for Patients with Colon Cancer: The First Follow-up Study: **World J Surg** 2021; 45: 1526.
53. Siebenhüner A, **Güller U**, Warschkow R. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. **BMC Cancer** 2020; 23: 246.
54. Rueff J, Weixler B, Viehl CT, Ochsner A, Warschkow R, **Güller U**, Mingrone W, Zuber M. Improved quality of colon cancer surveillance after implementation of a personalized surveillance schedule. **J Surg Oncol** 2020; 122: 529.
55. Jörger M, **Güller U**, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. **J Gastrointest Oncology** 2019; 10: 373.
56. Vangala DB, Cauchin E, Balmaña J, Wyrwicz L, van Cutsem E, **Güller U**, Castells A, Carneiro F, Hammel P, Ducreux M, van Laethem JL, Matysiak-Budnik T, Schmiegel W. Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. **Eur J Cancer**. 2018; 104: 91.
57. Jakob MO, **Güller U**, Ochsner A, Oertli D, Zuber M, Viehl CT. Lymph node ratio is inferior to pN-stage in predicting outcome in colon cancer patients with high numbers of analyzed lymph nodes. **BMC Surgery** 2018; 18: 81.
58. Ackermann CJ, **Güller U**, Jochum W, Schmied BM, Warschkow R. The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis. *Int J Colorectal Dis.* 2018 Jun 7. doi: 10.1007/s00384-018-3096-5.
59. Adamina M, Buchs NC, Penna M, Hompes R; St.Gallen Colorectal Consensus Expert Group. St.Gallen consensus on safe implementation of transanal total mesorectal excision. *Surg Endosc.* 2018; 32(3):1091.
60. Baraniskin A, Van Laethem JL, Wyrwicz L, **Güller U**, Wasan HS, Matysiak-Budnik T, Gruenberger T, Ducreux M, Carneiro F, Van Cutsem E, Seufferlein T, Schmiegel W. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. **Eur J Cancer**. 2017; 86: 305.
61. Viehl CT, Weixler B, **Güller U**, Dell-Kuster S, Rosenthal R, Ramser M, Banz V, Langer I, Terracciano L, Sauter G, Oertli D, Zuber M. Presence of bone marrow micro-metastases in stage I–III colon cancer patients is associated with worse disease-free and overall survival. **Cancer Medicine** 2017; 6(5):918-927.
62. Weixler B, Richenbacher A, Raptis D, Viehl CT, **Güller U**, Rüeff J, Zettl A, Frangioni J, Zuber M. Sentinel lymph node mapping with isosulfan blue or indocyanine green in colon cancer shows comparable results and identifies patients with decreased survival – A prospective single center trial. **World J Surgery** 2017; 41: 2378.
63. Weixler B, Viehl CT, Warschkow R, **Güller U**, Ramser M, Sauter G, Zuber M. Comparative analysis of tumor cell dissemination to the sentinel lymph nodes and to the bone marrow in patients with non-metastasized colon cancer. A prospective multicenter study. **JAMA Surgery** 2017; 152(10):912.
64. Warschkow R, **Güller U**, Cerny T, Schmied B, Plaswilm L, Putora PM. Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis. **Radiotherapy and Oncology** 2017; 123: 139.
65. Warschkow R, Tarantino I, Huttner F, Schmied B, **Güller U**, Diener M, Ulrich A. Predictive value of mucinous histology in colon cancer: a population-based, propensity score matched analysis. **Br J Cancer** 2016; 114: 1027.

66. Klasen J, **Güller U**, Muff B, Candinas D, Seiler CA, Fahrner R. Treatment options for spontaneous and postoperative sclerosing mesenteritis. **Journal of Gastrointestinal Surgery** 2016; 27: 761.
67. Tarantino I, Warschkow R, Schmied BM, **Güller U**, Mieth M, Cerny T, Büchler MW, Ulrich A. Predictive Value of CEA for Survival in Stage I Rectal Cancer: a Population-Based Propensity Score-Matched Analysis. **J Gastrointest Surg.** 2016; 20: 1213.
68. Warschkow R, Cerny T, Schmied B, **Güller U**, Thürlimann B, Jörgen M. A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction. **Br J Cancer** 2016; 115: 80.
69. Weixler B, Warschkow R, **Güller U**, Zettl A, von Holzen U, Schmied B and Zuber M. Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival. **BMC Cancer** 2016; 16: 106.
70. Ebinger S, Warschkow R, Tarantino I, Schmied B, **Güller U**, Schiesser M. Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: A population based SEER analysis. **Gastric Cancer** 2016; 19: 723.
71. Weixler B, Warschkow R, Zettl A, Riehle HM, **Güller U**, Viehl CT, Zuber M. Intranodal mapping using carbon dye results in more accurate lymph node staging in colon cancer patients. **World Journal of Surgery** 2015; 39: 2583.
72. Tarantino I, Achermann P, **Güller U**, Ulrich A, Schmied B, Horber D, Cerny T, Stanga Z, Warschkow R. Relative survival is an adequate estimate of cancer specific-survival: Baseline mortality-adjusted ten-year survival of 771 rectal cancer patients. **Annals of Surgical Oncology** 2013; 20(12):3877.
73. Croner R, Geppert C, Bader F, Nitsche U, Späth C, Rosenberg R, Zettl A, Matias-Guiu M, Tarragona J, **Güller U**, Stürzl M, Zuber M. Molecular staging of lymph node negative colon carcinomas by One-Step Nucleic Acid Amplification (OSNA) results in an upstaging of a quarter of patients in a prospective, European, multicenter study. **British Journal of Cancer** 2014; 110: 2544.
74. Larusson H, von Holzen U, Viehl CT, Rezaeian F, Riehle HM, Oertli D, **Güller U**, Zuber M. Blue dye injection does not induce dissemination of epithelial cells during SLN procedure in colon cancer patients. **International Journal of Colorectal Disease** 2014; 29: 689.
75. Castleberry AW, **Güller U**, Tarantino I, Berry MF, Brügger L, Warschkow R, Cerny T, Mantyh CR, Candinas D, Worni M. Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. **Journal of Gastrointestinal Surgery** 2014; 18: 1194.
76. Warschkow R, Tarantino R, Ukegjini K, Beutner U, **Güller U**, Schmied B, Müller SA, Schultes B, Thurnheer M. Concomitant cholecystectomy during laparoscopic Roux-en-Y gastric bypass in obese patients is not justified. A meta-analysis. **Obesity Surgery** 2013; 23: 397.
77. Meiers P, Cil T, **Güller U**, Zuber M. Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging? **Langenbecks Archives of Surgery** 2013; 398: 687.
78. Viehl C, **Güller U**, Langer I, Laffer U, Oertli D, Zuber M. Factors influencing the success of in vivo sentinel lymph node procedure in colon cancer patients. Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer. **World Journal of Surgery** 2013; 37: 873.
79. Worni M, **Güller U**, Meciejewski ML, Curtis L, Gandhi M, Pietrobon R, Jacobs DO, Ostbye T. Racial differences among patients undergoing laparoscopic gastric bypass surgery: a population-based trend analysis from 2002 to 2008. **Obesity Surgery** 2013; 23: 226.
80. Geyer M, **Güller U**, Beglinger Ch. Carbon dioxide insufflation in colonoscopy is safe: a prospective trial of 347 patients. **Diagn Ther Endosc.** 2012; 692532. doi: 10.1155/2012/692532
81. Warschkow R, Beutner U, Steffen T, Müller S, Schmied B, **Güller U**, Tarantino I. „Safe and early discharge after colorectal surgery due to C-reactive protein. A diagnostic meta-analysis of 1,832 patients” **Annals of Surgery** 2012; 256: 245.
82. Strauss und Torney M, **Güller U**, Rezaeian F, Loher S, Brosi P, Terracciano L, Zuber M. Tissue banking in a regional hospital: a promising future concept? First report on fresh frozen tissue banking in a hospital without an integrated institute of pathology. **World J Surg** 2012; 36: 2300.
83. Worni M, **Güller U**, Pietrobon R, Jacobs D, Ostbye T. Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the Nationwide Inpatient Sample from 2001-2008”, **Obesity Surgery** 2012; 22: 220.

84. Geyer M, **Güller U**, Beglinger C. Carbon dioxide insufflation in routine colonoscopy is safe and more comfortable? results of a randomized controlled double-blinded trial, **Diagnostic and Therapeutic Endoscopy**; 2012: 378906. doi: 10.1155/2011/378906.
85. Kaderli R, Stefanelli U, **Güller U**, Businger A. Women in surgery - a survey in Switzerland. **Archives of Surgery** 2010; 145(11): 1119-21.
86. Viehl CT, Ochsner A, Von Holzen U, Cecini R, **Güller U**, Laffer U, Oertli D, Zuber M. Inadequate quality of surveillance after curative surgery for colon cancer. **Annals of Surgical Oncology** 2010; 17(10): 2663.
87. Businger A, **Güller U**, Oertli D. Impact of the 50-work-hour limitation on training of surgical residents in Switzerland. **Archives of Surgery** 2010 ;145(6): 558.
88. Langer I, **Güller U**, Viehl CT, Oertli D, Zuber M. Axillary lymph node dissection in early-stage breast cancer patients with SLN micro-metastases can be safely omitted. Long-term outcomes of a prospective study. **Annals of Surgical Oncology** 2009; 16(12): 3366.
89. Langer I, **Güller U**, Hsu Schmitz SF, Ladewig A, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M. Sentinel lymph node biopsy is associated with improved survival compared to level I&II axillary lymph node dissection in node negative breast cancer patients. **European Journal of Surgical Oncology** 2009; 35: 805.
90. Muscari F, Suc B, Msika S, Hay JM, Flamant Y, Fournanier G, **Güller U**, Lorimier G, Dziri C, Fingerhut A. Surgeon dependent predictive factors for mortality after elective colorectal resection and immediate anastomosis for cancer or non-acute diverticular disease. Multivariable analysis of 2,605 patients. **Journal of the American College of Surgeons** 2008; 207: 888.
91. Coburn NG, **Güller U**, Baxter NN, Kiss A, Ringash J, Swallow CJ, Law CH. Adjuvant therapy for resected gastric cancer – rapid, yet incomplete adoption following the results of the Intergroup 0116 trial. **International Journal of Radiation Oncology, Biology, and Physics** (Impact Factor: 4.46) 2008; 70: 1073.
92. Adamina M, Weber WP, Rosenthal R, Schuhmacher R, Zajac P, **Güller U**, Oertli D, Zuber M, Heberer M, Spagnoli M. "Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labelled clinical trial". **Contemporary Clinical Trials** (Impact Factor: 1.33) 2008; 29: 165.
93. Coburn NG, Govindarajan A, Law CH, **Güller U**, Kiss A, Ringash J, Swallow CJ, Baxter NN. Stage-specific benefit of adjuvant therapy following gastric cancer resection: A population-based analysis of 4,041 patients. **Annals of Surgical Oncology** 2008; 15: 500.
94. Lehmann K, **Güller U**, Bugnon S, Zuber M. Interdisciplinary tumour boards in Switzerland: quo vadis? **Swiss Medical Weekly** (Impact Factor: 1.346) 2008; 138: 123.
95. Rosenthal R, Viehl CT, **Güller U**, Weber WP, Adamina M, Spagnoli GC, Heberer M, Zuber M. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. **Journal of the American College of Surgeons** 2008; 207:95.
96. Langer I, **Güller U**, Viehl CT, Berclaz G, Koechli OR, Moch H, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. **Breast Cancer Research and Treatment** 2009; 113: 129.
97. Langer I, **Güller U**, Berclaz G, Koechli OR, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN & completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 Patients. **Annals of Surgery** (Impact Factor: 7.68) 2007; 245: 452.
98. Langer I, **Güller U**, Koechli OR, Berclaz G, Singer G, MD, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger E, Zuber M. Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study. **Annals of Surgical Oncology** (Impact Factor: 3.33) 2007; 14: 1896.
99. Daetwiler S, **Güller U**, Schob O, Adamina M. Early introduction of laparoscopic sigmoidectomy during residency: a safe and feasible training concept. **British Journal of Surgery** (Impact Factor: 4.01) 2007; 94: 634.

100. Adamina M, **Güller U**, Bracci L, Heberer M, Spagnoli GC, Schumacher R. Clinical applications of virosomes in cancer immunotherapy. **Expert Opinion on Biological Therapy** (Impact Factor: 2.71) 2006; 6: 1113.
101. Freedman J, Pietrobon R, **Güller U**, Benjamin DK, Higgins LD, Pan D. National trends in health care utilization and racial and socio-economic disparities in pediatric pyogenic arthritis. **Journal of Pediatric Orthopaedics** (Impact Factor: 1.15) 2006; 26: 709.
102. Adamina M, **Güller U**, Weber W, Oertli D. Propensity scores and the surgeon. **British Journal of Surgery** (Impact Factor: 3.7) 2006; 93:389.
103. Viehl CT, **Güller U**, Hamel CT, Riehle HM, Plaass C, Marti WR, Oertli D, Zuber M. Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients. **World Journal of Surgery** (Impact Factor: 1.91) 2006; 30: 453.
104. Grapow M, Von Wattenwyl R, **Güller U**, Beyersdorf F, Zerkowski HR. Randomized controlled trials do not reflect reality – real-world analysis are critical for treatment guidelines. **Journal of Thoracic and Cardiovascular Surgery** (Impact Factor: 1.02) 2006; 132: 5.
105. Haier J, Owzcareck M, **Güller U**, Spagnoli GC, Senniger N, Kocher T. Expression of MAGE-A/Cancer testis antigen in esophageal squamous cell carcinomas. **Anticancer Research** (Impact Factor: 1.48) 2006, 26: 2281.
106. Nitin JB, Higgins LD, **Güller U**, Pietrobon R, Katz JN. Trends in epidemiology of total shoulder arthroplasty in the United States, 1990 – 2000. **Arthritis and Rheumatism** (Impact Factor: 7.14) 2005, 52: 3928.
107. Jain N, Pietrobon R, **Güller U**, Ahluwalia AS, Higgins LD. Influence of provider volume on length of stay, operating room time, and discharge status for rotator cuff repair: an analysis based on 9,973 patients. **Journal of Shoulder & Elbow Surgery** (Impact Factor: 0.88) 2005; 14: 407.
108. Jain N, Hocker S, Pietrobon R, **Güller U**, Bathia N, Higgins LD. Total arthroplasty versus hemiarthroplasty for glenohumeral osteoarthritis: role of provider volume. **Journal of Shoulder & Elbow Surgery** (Impact Factor: 0.88) 2005; 14: 361.
109. Jain N, Pietrobon R, **Güller U**, Bond TK, Kazani S, Higgins LD. Comorbidities increase complication rates in patients having arthroplasty. **Clinical Orthopedics and Related Research** (Impact Factor: 1.53) 2005; 435: 232.
110. Jain B, Laden F, **Güller U**, Shankar A, Kazani S, Garshick E. Relation between blood lead levels and childhood anemia in India. **American Journal of Epidemiology** (Impact Factor: 5.07) 2005; 161: 1.
111. Langer I, Marti WR, **Güller U**, Moch H, Harder F, Oertli D, Zuber M. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micro-metastases: prospective analysis of 150 patients after SLN biopsy. **Annals of Surgery** (Impact Factor: 5.94) 2005; 241:152.
112. Purves H, Pietrobon R, Hervey Sheleika, **Güller U**, Miller W, Ludwig K. Relationship between surgeon caseload and sphincter preservation in rectal cancer patients. **Diseases of the Colon and Rectum** (Impact Factor: 2.31) 2005; 48: 195.
113. Jain N, Pietrobon R, **Güller U**, Shankar A, Ahluwalia AS, Higgins LD. Effect of provider volume on resource utilization for surgical procedures of the knee. **Knee Surgery Sports Traumatology Arthroscopy** (Impact Factor: 1.05) 2005; 13: 302.
114. Langer I, Kocher T, **Güller U**, Torhorst J, Oertli D, Harder F, Zuber M. Long-term outcomes of breast cancer patients after endoscopic axillary lymph node dissection: a prospective analysis of 52 patients. **Breast Cancer Research and Treatment** (Impact Factor: 3.1) 2005; 90: 85.
115. Bolli M, Schultz-Thater E, Zajac P, **Güller U**, Feder C, Sanguedolce F, Carafa V, Terracciano L, Spagnoli GC, Tornillo L. Co-expression of NY-ESO-1/LAGE-1 with MAGE cancer/testis tumor associated antigens: a potentially successful new avenue for specific immunotherapy. **International Journal of Cancer** (Impact Factor: 4.69) 2005; 115: 960.
116. Raynor M, Pietrobon R, **Güller U**, Higgins L. Cryotherapy after ACL reconstruction: a meta-analysis. **The Journal of Knee Surgery** 2005; 18; 123.
117. Jain NB, Higgins L, Ozumba D, **Güller U**, Cronin M, Pietrobon R, Katz JN. Trends in epidemiology of knee arthroplasty in the United States, 1990-2000. **Arthritis and Rheumatism** (Impact Factor: 7.14) 2005; 52: 3928.

118. Jain N, Pietrobon R, Hocker S, **Güller U**, Shankar A, Higgins LD. The relation between provider volume and outcomes for shoulder arthroplasty. **American Journal of Bone and Joint Surgery** (Impact Factor: 1.92) 2004; 86: 496.
119. Cotton J, Nielson K, **Güller U**, Steele S, Klein SM, Greengrass R, Pietrobon R. Increased body mass index and ASA physical status are risk factors for block failure in ambulatory surgery - an analysis of 9,342 blocks. **Canadian Journal of Anaesthesiology** (Impact Factor: 1.20) 2004; 51: 810.
120. Pietrobon R, Taylor M, **Güller U**, Higgins LD, Jacobs DO, Carey T. Predicting gender differences as latent variables; summed scores, and individual item responses: a methods case study. **Health and Quality of Life Outcomes** 2004; 2:59.
121. Pietrobon R, **Güller U**, Martins H, Menezes AP, Higgins LD, Jacobs DO. A suite of web applications to streamline the interdisciplinary collaboration in secondary data analyses. **BMC Medical Research Methodology** 2004; 4: 29.
122. Bosch B, **Güller U**, Schnider A, Maurer R, Heberer M, Metzger U, and Marti WR. Peri-operative detected disseminated tumor cells represent an independent prognostic factor in colorectal cancer patients. **British Journal of Surgery** (Impact Factor: 3.77) 2003; 90(7):882.
123. Viehl CT, Hamel CT, Marti WR, **Güller U**, Eisner L, Stammberger U, Terracciano L, Spichtin HP, Harder F, Zuber M. Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumour size. **World Journal of Surgery** (Impact Factor: 1.91) 2003; 27: 1285.
124. Zajac P, Oertli D, Marti WR, Adamina M, Bolli M, **Güller U**, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G. Phase I/II clinical trial of a non-replicative vaccinia virus expressing multiple HLA-A0201 restricted tumor associated epitopes and costimulatory molecules in metastatic melanoma patients. **Human Gene Therapy** (Impact Factor: 4.97) 2003; 14: 1497.
125. Hervey S, Purves H, **Güller U**, Toth AP, Vail TP, and Pietrobon R. Analysis of the volume-outcomes relationship in patients undergoing total knee arthroplasty based on a nationwide database. **American Journal of Bone and Joint Surgery** (Impact Factor: 1.92) 2003; 85(9): 1775.
126. Bolli M, Kocher T, Adamina M, **Güller U**, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC. Tissue microarray evaluation of MAGE tumor associated antigens expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. **Annals of Surgery** (Impact Factor: 6.07) 2002; 236(6): 768.
127. Baykut D, **Güller U**, Gebhard MM, Kadipasaoglu K, Zerkowski HR, Frazier OH: Intravascular detection of myocardial ischemia by spectrometry in the near infrared spectrum in experimental animals. **Archives des Maladies du Coeur et des Vaisseaux** (Impact Factor: 0.41) 2001; 94(9): 995.
128. Muhlhaupt B, **Güller U**, Anabitarte M, Güller R, Fried M. Lymphocytic colitis: clinical presentation and long term course. **Gut** (Impact Factor: 5.11) 1998; 43: 629.

Publikationen/Buchkapitel (nicht peer-reviewed)

129. Ackermann CJ, **Güller U**, Joerger M. Exzellentes Tumorsprechen nach sequentieller Kombinations-Immuncheckpoint-Inhibition und Regorafenib bei einem Patienten mit fortgeschrittenen hepatozellulären Karzinom. **Schweizer Krebsbulletin** 2021; 2: 178.
130. Ntellas P, Güller U. Highlights of ESMO & ASCO 2021 on Upper Gastrointestinal Malignancies. **Leading Opinions Hämatologie & Onkologie** 8/2021.
131. **Güller U**, Warschkow R, Ackermann AJ, Schmied B, Cerny T, Ess S. Weitwinkel- statt Teleobjektiv: Patienten im Fokus der HSM-Debatte! **Schweizerische Aerztezeitung** 2018; 99(1920):631.
132. **Güller U**, Warschkow R, Ackermann CJ, Schmied BM, Cerny T, Ess S. Reply to technical comment on: Güller et al. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. *Swiss Med Wkly.* 2018; 148:w14583.
133. Ackermann C, **Güller U**. Medizinisch-onkologische Therapie des Pankreaskarzinoms: Update für den Nicht-Onkologen. **Therapeutische Umschau** 2016; 73: 511.
134. Ackermann C, Güller U, Cerny T. Kardiotoxizität von Imatinib bei einem Patienten mit gastrointestinalem Stromatumor. **Krebsbulletin** 4. 2015.

135. Tarantino I, Warschkow R, **Güller U**. Palliative primary tumor resection in patients with metastatic colorectal cancer: for whom and when? **Annals of Surgery** 2017; 265(4):e59.
136. **Güller U**. Laparoscopic versus open total mesorectal excision for rectal cancer: a reality check in the context of an improvement project. Commentary. **British Journal of Surgery** 2013; 100(10):1375.
137. Banz V, Gsponer T, Candinas D, **Güller U**. Response to Letter to the Editor Re: "Population-Based Analysis of 4113 Patients With Acute Cholecystitis. Defining the Optimal Time-Point for Laparoscopic Cholecystectomy. **Annals of Surgery** 2014; 259: e3.
138. Worni M, Schudel H, **Güller U**. Elektive Splenektomie bei Erwachsenen – Vorbereitung, Durchführung und Nachbetreuung. **Therapeutische Umschau** 2013; 70: 171.
139. Gass M, **Güller U**. Re: Bilateral total extraperitoneal inguinal hernia repair (TEP) has outcomes similar to those for unilateral TEP: population-based analysis of prospective data of 6,505 patients. **Surg Endosc** 2012; 26(5):1364.
140. **Güller U**. Prospective database of the Swiss Association of Laparoscopic and Thoracoscopic Surgery: goldmine or fool's gold? **Swiss Knife** (official Swiss surgical journal) 1/2011.
141. Viehl CT, Langer I, **Güller U**. et al. Prognostic impact and therapeutic implication of sentinel lymph node micro-metastases in early stage breast cancer patients. **Journal of Surgical Oncology** 2011; 103: 531.
142. **Güller U**. Wissenschaftliches Schreiben ist lernbar. **Schweizerische Aerztezeitschrift**, September 2011.
143. Gass M, **Güller U**. Abdominal pain: Perforation and abdominal inflammation. **Therapeutische Umschau** 2011; 68: 473.
144. Fahrner R, **Güller U**. Abdominal pain without clinical correlate. **Therapeutische Umschau** 2011; 68:456.
145. **Güller U**, Macpherson A, Candinas D. Die Blackbox des schmerzhaften Abdomens **Therapeutische Umschau** 2011; 68: 440.
146. **Güller U**, Macpherson A. Inflammatory bowel disease and irritable bowel syndrome. **Therapeutische Umschau** 2011; 68: 459.
147. **Güller U**, Langer I, Zuber M. In reply: micrometastases in breast cancer sentinel lymph node. **Annals of Surgical Oncology** 2010; 17:938.
148. Herrle F, **Güller U**. **Evidence-Based Surgery Series. Part 1:** Interpreting study designs in surgical research - a practical guide for surgeons and surgical residents. **Zeitschrift für Herz-, Thorax- und Gefäßchirurgie** 2009; 2: 115.
149. Herrle F, **Güller U**. **Evidence-Based Surgery Series. Part 2:** Interpreting systematic reviews and meta-analyses. A practical guide for surgeons and surgical residents. **Zeitschrift für Herz-, Thorax- und Gefäßchirurgie** 2009; 23: 182.
150. Herrle F, **Güller U**. **Evidence-Based Surgery Series. Part 3:** Bias in surgery: the 7 deadly sins. **Zeitschrift für Herz-, Thorax- und Gefäßchirurgie** 2009; 23: 235.
151. **Güller U**, Klein LV, Hagen J. Safety and effectiveness of bariatric surgery: Roux-en-Y gastric bypass is superior to gastric banding in the management of morbidly obese patients. A response to the reply by Bhoryl et al. **Patient Safety in Surgery** 2009; 3: 20.
152. **Güller U**, Kempfski O, Zuber M. The bumpy path to successful academic surgery – a roadmap for the resident. **European Surgical Research** 2009; 43: 253.
153. **Güller U**. Meta-analyses: advantages and caveats. **Swiss Knife** (official Swiss surgical journal) 2008, vol. 4.
154. **Güller U**. A fellowship in surgical oncology at the University of Toronto – a Swiss perspective. **Swiss Knife** (official Swiss surgical journal) 2008, vol 2.
155. Langer I, **Güller U**, Viehl CT, Zuber M. Sentinel lymph node metastases in breast cancer: prognostic relevance and therapeutic implications. Chapter in: From local invasion to metastatic cancer. Involvement of distant sites through the lymphovascular system. Leong SPL (ed). Humana Press / Springer. 2009: 339-345.
156. Zuber M, Viehl CT, **Güller U**, Langer I. Follow-up recommendations for patients after curative treatment of invasive breast cancer. **Therapeutische Umschau** 2008; 65: 319.
157. Grapow M, **Güller U**, Zerkowski HR. Wahrnehmung und Wirklichkeit: zur Bedeutung unterschiedlicher Studientypen für den klinischen Alltag; In : **Risiko und Qualität in der Herzchirurgie**. Steinkopff 2006

158. **Güller U**. A fellowship in surgical oncology: fantasy or feasible? **Swiss Knife** (official Swiss surgical journal) 2006; 2: 19.
159. **Güller U**, Oertli D. Workshop for General Surgery Board Certification FMH: „Preoperative Risk-Assessment“, March 2006.
160. **Güller U**, Mayr M. Secondary and tertiary hyperparathyroidism. In: **Surgery of the Thyroid and Parathyroid Gland** (D. Oertli and R. Udelsman), Springer 2006.
161. Pfefferkorn U, Hamel CT, **Güller U**, Sonnet S, Oertli D. Magenruptur nach Weihnachtsessen. **Swiss Medical Forum** 2005; 5: 1265.
162. **Güller U**, Oertli D. Sample size matters – a guide for surgeons. **World Journal of Surgery** (Impact Factor: 1.91) 2005; 29: 601.
163. Brett W, Hirschmann M, **Güller U**, Zerkowski HR: CABG vs PCI: what is the evidence? **Cardiac Surgery Today** 2005; 2: 53.
164. Braga L, **Güller U**, Semelka RC. Pre-, peri-, and post-treatment imaging of liver lesions. **Radiologic Clinics of North America** (Impact Factor: 1.85) 2005; 43:915.
165. **Güller U**, Oertli D, Zuber M. Positron emission tomography in the staging and management of breast cancer. **British Journal of Surgery** (Impact Factor: 3.72) 2005 (letter).
166. Pietrobon R, **Güller U**, Higgins LD, Nunley J. Levels of evidence in orthopedic surgery – a step in the right direction, but does it stand alone? (letter) **American Journal of the Bone and Joint Surgery** 2004 (Impact Factor: 1.92).
167. **Güller U**, Zuber M, Marti WR, Heberer M, Oertli D. Challenges in performing clinical trials in surgical oncology. **Swiss Knife** (official Swiss Surgical Journal) 2004; 1: 23.
168. **Güller U**, Buhler L, Clavien PA. “Science Writing Courses” organized by the Research Section of the Swiss Surgical Society, **Swiss Knife** (official Swiss surgical journal) 2004; 1: 26.
169. Braga L, **Güller U**, Semelka RC. Modern liver imaging. **Surgical Clinics of North America** (Impact Factor: 1.59) 2004; 84: 375.
170. **Güller U**. The perplexing problem of prohibitively large sample sizes. **Swiss Knife**, (official Swiss surgical journal) 2004; 2: 22.
171. **Güller U**, Buhler L, Clavien PA. Statistics in medicine (editorial). **Swiss Medical Weekly** (Impact Factor: 1.16) 2003; 133: 521.
172. Viehl CT, **Güller U**, Kocher T. Ich weiss nicht, ob ich in zehn Jahren noch operativ tätig sein werde. **Unionszeitung der Schweizerischen Chirurgischen Fachgesellschaften** 2000; 4: 5.

Referate/Wissenschaftliche Meetings

Über 300 Referate an nationalen und internationalen Meetings.

Visiting Professor/Eingeladener Referent (Auswahl) in:

Phoenix/AZ/USA
St. Louis/MO/USA
San Antonio/TX/USA
Orlando/FL/USA
Toronto/ON/Canada
Montreal/Québec/Canada
Barcelona/ESP
Hamburg/DE
München/DE
Prague/Czech Republic
Madrid/ESP
Leuven/BE
Athen/GR
Marseille/FR
Rom/IT

Lehrtätigkeit/Kongressorganisation

2021 - 2026	Wissenschaftliches Komitee und Referent «Best of GI-Oncology»
2020 - 2023	Wissenschaftliches Komitee «ESMO in the Alps» (Moderation ESMO-Direktübertragung, 4 Kongresse)
2016 - 2023	Young Oncology Academy (Mentoring, 8 x)
2019	Leiter Organisationskomitee 3. ESDO Masterclass, St. Gallen
2016 - 2026	Wissenschaftliches Komitee «Chicago in the Mountains», Flüeli-Ranft/Sarnen (Moderation ASCO-Direktübertragung, bislang 11 Kongresse)
2016 - 2026	Wissenschaftliches und Organisationskomitee ASCO GI in the Mountains; Zürich (bislang 11 Kongresse)
2013 - 2026	Mitglied des Organisations- und/oder wissenschaftlichen Komitees der jährlichen Ärztefortbildungskurse in Medizinischer Onkologie, St. Gallen (bislang 14 Kurse)
2002 - 2013	Mitglied des Organisations- und wissenschaftlichen Komitees der Swiss Courses in Cancer Surgery (insgesamt 6 Kurse)
2008	Organisator des Scientific Writing Courses (2 Tage) an der Universität Toronto, Toronto/Canada
2007 – 2018	Workshop “In 90 minutes to the statistical Elysium” an den Jahreskongressen der Schweizerischen Gesellschaft für Chirurgie (insgesamt 12 Kurse)
2003 - 2012	Workshop “Basic Statistics for Surgeons”, Basic Science Writing Kurse, Uetliberg/ZH, 2003 – 2013 (insgesamt 10 Kurse)
2003 - 2012	Organisator der Annual Basic Scientific Writing Kurse, Uetliberg/ZH (1x/annum, insgesamt 10 Kurse)
2004 - 2008	Organisator des Advanced Grant Writing Courses, Brienz (Kurslänge: 3 Tage, 1x/annum)
2004 - 2011	Workshop “All a Surgeon Needs to Know about Sample Size Computations”, Advanced Grant Writing Kurse, Brienz
2002	Unterrichten von angehenden Physicians` Assistants in klinischer Forschung, Statistik und medizinischer Epidemiologie (Masterstudiengang, PAP 255, 1 Semester), Duke Universität, Durham/NC, USA

Supervision und Betreuung von Arbeiten für den Masterstudiengang zum Physician Assistant (PA), Duke University Medical Center (Course PAP 305)

- 2002 *Helicobacter pylori* infection and its effects on chronic thrombocytopenic purpura. Charles E. Lott, MHS
- 2002 *Diagnostic utility of laparoscopy compared with standard diagnostic tools in the staging of pancreatic cancer*, Jennifer Perkins, MHS
- 2002 *Should laparoscopic colectomy become the standard of care in the treatment of diverticulitis?* Monica S. Piece, MHS
- 2002 *Use of positron emission tomography in the staging of axillary lymph node metastases in breast cancer patients*. Suzanne Morton, MHS
- 2002 *Do disseminated tumor cells have an impact in colorectal cancer patients?* Danielle Parrish, MHS